Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $1,494,368.70 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 2,410 shares of the stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $620.07, for a total transaction of $1,494,368.70. Following the transaction, the chief executive officer directly owned 386,892 shares of the company’s stock, valued at $239,900,122.44. This trade represents a 0.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Medpace Trading Down 4.2%

Shares of MEDP stock opened at $598.08 on Friday. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The stock’s 50-day moving average price is $599.99 and its 200-day moving average price is $520.63. The stock has a market capitalization of $16.69 billion, a price-to-earnings ratio of 35.06, a price-to-earnings-growth ratio of 2.78 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the previous year, the business earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Medpace

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Johnson Financial Group Inc. bought a new stake in Medpace in the second quarter worth $27,000. Jones Financial Companies Lllp purchased a new position in Medpace during the second quarter worth $30,000. Allied Private Wealth LLC bought a new position in Medpace during the second quarter valued at $31,000. Kilter Group LLC bought a new position in Medpace during the second quarter valued at $31,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Medpace during the second quarter valued at $34,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on MEDP shares. Leerink Partners set a $620.00 target price on Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada boosted their price target on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Barclays set a $600.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group reiterated a “hold” rating on shares of Medpace in a research report on Monday, September 14th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $602.27.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: UBS upgraded Medpace from “sell” to “neutral” (effectively “hold”) and raised its price target to $673 from $405. The revised target remains above the recent trading level, suggesting UBS sees less downside risk than previously expected. UBS upgrades Medpace and raises price target
• Positive Sentiment: Medpace’s latest reported quarter showed solid momentum, with revenue increasing 17.2% year over year to $707.3 million and adjusted earnings of $4.25 per share exceeding analyst expectations. Management’s fiscal 2026 earnings guidance remains supportive of the long-term growth narrative. Medpace reports 17.2 percent revenue growth
• Neutral Sentiment: Analyst sentiment remains mixed. Several firms have “hold” ratings, while others maintain bullish views; the broader consensus is near a hold rating, indicating that expectations for Medpace’s strong growth are already reflected in its relatively high valuation.
• Negative Sentiment: CEO August Troendle sold 21,966 shares for approximately $13.7 million on September 30, following the sale of 26,701 shares worth about $16.6 million one day earlier. The combined sales totaled roughly $30.3 million and reduced his direct ownership by about 13% across the two transactions. Additional smaller reported sales add to concerns about insider confidence, even though Troendle still owns a substantial stake. Medpace CEO stock sale SEC filing

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.